Eton Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 14, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 14, 2024
ETON$64.35+14.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(In thousands)
| For the years ended | |||
|---|---|---|---|
| December 31, | December 31, | December 31, | |
| 2023 | 2022 | 2021 | |
| Cash flows from operating activities | |||
| Net loss | $(936) | $(9,021) | $(1,955) |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | |||
| Stock-based compensation | 3,137 | 4,218 | 3,381 |
| Depreciation and amortization | 901 | 1,774 | 462 |
| Debt discount amortization | 117 | 127 | 148 |
| Gain on forgiveness of PPP loan | — | — | (365) |
| Gain on sale of equipment | — | — | (181) |
| Changes in operating assets and liabilities: | |||
| Accounts receivable | (1,559) | 3,619 | (5,423) |
| Inventories | (354) | (7) | 692 |
| Prepaid expenses and other assets | 161 | 1,902 | (1,026) |
| Accounts payable | 53 | (8) | (570) |
| Accrued liabilities | 5,295 | 2,217 | 116 |
| Net cash provided by (used in) operating activities | 6,815 | 4,821 | (4,721) |
| Cash used in investing activities | |||
| Proceeds from sale of equipment | — | — | 700 |
| Purchases of property and equipment | — | (38) | (9) |
| Purchase of product licensing rights | (775) | (2,750) | (3,250) |
| Net cash used in investing activities | (775) | (2,788) | (2,559) |
| Cash flows from financing activities | |||
| Debt paydown | (1,155) | (385) | (150) |
| Net proceeds from employee stock purchase plan and stock option and stock warrant exercises | 198 | 251 | 541 |
| Net cash (used in) provided by financing activities | (957) | (134) | 391 |
| Change in cash and cash equivalents | 5,083 | 1,899 | (6,889) |
| Cash and cash equivalents at beginning of year | 16,305 | 14,406 | 21,295 |
| Cash and cash equivalents at end of year | $21,388 | $16,305 | $14,406 |
| Supplemental disclosures of cash flow information | |||
| Cash paid for interest | $842 | $730 | $815 |
| Cash paid for income taxes | $247 | $— | $— |
| Supplemental disclosures of non-cash investing and financing activities: | |||
| Adjustment of operating lease right-of-use assets and liabilities due to tenant allowance | $29 | $— | $— |
| Right-of-use assets obtained in exchange for lease liabilities | $— | $188 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.